Affimed (NASDAQ:AFMD) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Affimed (NASDAQ:AFMD – Free Report) in a research note issued to investors on Tuesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Other analysts also recently issued reports about the company. HC Wainwright restated a buy rating and issued a $5.00 price objective on shares […]

Leave a Reply

Your email address will not be published.

Previous post Arcutis Biotherapeutics (NASDAQ:ARQT) Upgraded by Mizuho to Buy
Next post China tests first electric aircraft